|
|
 |
|
Viewing report
|
|
|
|
Cancer Drug Discoveries: What the Future Holds
Espicom Business Intelligence Ltd, May 2007, Pages: 652
Understand the prospects for this US$47.2 billion market
- Unique market share, sales forecasts by product to 2012
- A comprehensive examination of five major oncology areas:
Breast cancer: Focusing on the changes in the gold standard, the impact of novel therapies on treatment and the new drugs in development.
Non-small cell lung cancer: Focusing on the launch of novel therapies into the arena; are they dramatically changing the way NSCLC is treated?
Colorectal cancer: Focusing on the evolution of new treatment regimes, the development of new formulations and advances in cancer vaccines.
Prostate cancer: Focusing on current hormonal therapies, the treatment of HRPCA and improvements in screening.
Renal cancer: With up to 9 new launches by 2012, renal cancer is in an exciting stage of development.
- Critical competitive evaluation and scoring of current and upcoming products
For each therapy area the report provides:
THE FACTS
- Risk factors, how the disease affects patients, diagnosis and stages of the disease
PATIENT STATISTICS
- Prevalence in the US, Europe and Japan
- Diagnosis and treatment rates
THE MARKET
- Global cancer market (all types)
- Global cancer market split by US, Europe and Japan (by specific cancer)
- The companies - market share 2006 and 2012
CURRENT TREATMENTS
- Interventions by type
- Unique five point competitive assessment of current therapies and companies involved
- Sales forecasts by product 2006A-2012E R&D: DRUGS IN PHASE II/III
- Focus on new classes of drugs and the companies involved
- Unique competitive assessment of current therapies and companies involved
- Sales forecasts by product from year of launch to 2012
COMPETITOR ANALYSIS - PRODUCTS & COMPANIES
- Winners and losers in the future
EXTENSIVE APPENDICES
- Statistics on key areas such as patient population, launch probability
In 2006, we estimate the global anticancer market was worth over US$47.2 billion (+12% YoY) accounting for 7.3% of global pharmaceutical sales (US$650 billion). Global sales include those of cytotoxics, innovatives (novel therapies, monoclonal antibodies) and antihormonals plus supportive care (drugs given to patients to prevent or treat the toxicities associated with chemotherapy) which accounted for nearly half of global sales.
By 2012, the global cancer market is expected to generate sales in excess of US$65 billion due to growth in the sales of existing products and the launch of nearly 60 new products, which will account for around 30% of total drug launches. These will offset the decline in sales of cytotoxics and antihormonals, which face generic sales erosion and the uptake of newer products in preference to these older agents.
The cancer treatment market is set to change radically as newer targeted therapies replace broader spectrum treatments. They are generally better tolerated, less toxic and provide better patient outcomes. A trend also to be noted is the rise of combination therapies and earlier drug intervention, often at the surgical stage. Against these positive trends is a growing concern about the rising cost of cancer drugs. With several products now costing US$10,000+, the balance of meeting medical demands against the cost of treatment is an issue in all developed countries.
This new 650+ page report Cancer Drug Discoveries: what the future holds covers the major cancer sectors and provides a unique and independent assessment of the markets, products, companies and research that are driving change.
Comprehensive assessment for robust conclusions
- To give forecasts and assessments which are reliable the following is taken into account for all products evaluated:
the probability of a drug reaching the market based on DiMasi (2001) and Reichert (2001) studies;
- the strength of the scientific rationale for the development of a product;
- the availability of proof-of-concept data;
- pharmacokinetic properties of the drug, that is, selectivity and efficacy;
- financial support for product development, potential co-marketing deals;
- - the company’s history of developing and promoting cancer products;
- competition within the market – existing and Phase II/III drugs;
- the impact of generic competition.
Unique competitor ratio analysis criteria for up and coming products
- The drugs in the report have been chosen for evaluation based on a number of parameters:
- they have new/novel late Phase clinical data (Phase II to III);
- they have been highlighted in company reports or R&D presentations as key drivers for the company;
- they have a novel mechanism of action that makes them stand out amongst their competitors – not a ‘me too’ drug;
- their approval could drastically change the course of treatment of a disease, i.e. new formulations, combination therapies, vaccines to prevent the disease, drugs to improve the symptoms of the disease, etc;
- they have a relatively high chance of entering the marketplace by 2012.
Customers who bought this item also bought
Cancer Therapies - Global Strategic Business Report
Cancer Therapies - Global Market Opportunities
Commercial Insight: Antihormonal Cancer Therapies
Drug Delivery Technology - Revolutionizing Cancer Therapies
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
The Cancer Market Outlook to 2012
Global Cancer Treatment Forecast to 2012
Cancer Therapeutics Markets
Drug Delivery in Cancer - Technologies, Markets and Companies
Cancer Drug Discoveries: What the Future Holds: Colorectal Cancer Chapter
Innovations in Cancer: Novel Therapeutics, New Diagnostics and Future R&D Strategies
Pipeline Insight: Molecular Targeted Cancer Therapies: Can Anything Else Revolutionize the Market?
|
|
|
|
